HealthCap IX Secures €48M to Propel Transformative Life Sciences Innovations

HealthCap is proud to announce a significant milestone with the successful closing of HealthCap IX, having raised EUR 48,000,000 in this latest funding round. As a leading European venture capital firm that invests exclusively and globally in life sciences, HealthCap has long been at the forefront of catalyzing innovation by backing companies that address major unmet medical needs. Since its inception in 1996, HealthCap has raised over EUR 1.2 billion, built more than 125 companies, and facilitated the public listing of over 45 ventures, earning a reputation as one of the largest specialized providers of venture capital within life sciences in Europe. This latest fund will further strengthen our mission to support breakthrough therapies and transformative treatments aimed at combating diseases where conventional therapies have fallen short. The new capital will be dedicated to nurturing companies that are developing next-generation pharmaceuticals and innovative medical device products—many of which have already achieved market approval and have had a profound impact on patient care. By investing in groundbreaking research and high-potential early-stage companies, HealthCap IX is set to accelerate the development of novel therapies with the potential to change medical practice and improve patient outcomes. Our history of creating significant value for stakeholders, from visionary founders and dedicated physicians to patients around the world, reinforces our commitment to driving progress within the life sciences sector. We are excited about the opportunities this new fund will unlock and remain dedicated to our mission of advancing transformative innovations that can reshape healthcare on a global scale.